Aethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report issued on Friday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a report on Monday, March 10th.

Aethlon Medical Price Performance

NASDAQ:AEMD opened at $0.37 on Friday. The company’s fifty day moving average price is $0.56 and its 200-day moving average price is $0.50. Aethlon Medical has a 1-year low of $0.24 and a 1-year high of $1.79. The firm has a market capitalization of $5.30 million, a P/E ratio of -0.23 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.09. Equities analysts anticipate that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Institutional Trading of Aethlon Medical

A number of hedge funds have recently added to or reduced their stakes in the company. Allegiance Financial Group Advisory Services LLC purchased a new position in Aethlon Medical in the fourth quarter valued at $26,000. Virtu Financial LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter valued at about $81,000. Renaissance Technologies LLC purchased a new position in shares of Aethlon Medical in the 4th quarter valued at about $25,000. Sassicaia Capital Advisers LLC purchased a new position in shares of Aethlon Medical in the 4th quarter valued at about $31,000. Finally, Boothbay Fund Management LLC acquired a new position in Aethlon Medical in the 4th quarter worth about $186,000. 1.99% of the stock is owned by hedge funds and other institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.